Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28603947 | 0.76 | PTGS2 (0.47) | — | |
| SCHEMBL1521833 | 0.76 | CYP2A6 (0.47) | CYP2A6CYP17A1 | |
| SCHEMBL8649337 | 0.76 | CYP2A6 (0.60) | CYP2A6CYP17A1 | |
| SCHEMBL2876155 | 0.75 | PGR (0.38) | — | |
| SCHEMBL28590566 | 0.73 | PTGS2 (0.47) | — | |
| SCHEMBL7451509 | 0.72 | CYP2A6 (0.56) | CYP2A6CYP17A1 | |
| SCHEMBL2113306 | 0.71 | CYP2A6 (0.58) | CYP2A6 | |
| SCHEMBL533513 | 0.70 | PDPK1 (0.60) | CYP2A6 | |
| SCHEMBL28275550 | 0.70 | CYP2A6 (0.39) | CYP2A6 | |
| SCHEMBL28274314 | 0.70 | ADRA2A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | claimed |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | claimed |
| US-20070149584-A9 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | JOHN VARGHESE | 2007-06-28 | — | — | US | claimed |
| EP-1773756-A2 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| EP-1773758-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| EP-1735293-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1730125-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-13 | — | — | EP | claimed |
| EP-1729755-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-13 | — | — | EP | claimed |
| US-20060135581-A1 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | claimed |
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | claimed |
| WO-2006010094-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | claimed |
| WO-2006010095-A2 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS INC. (US) | 2006-01-26 | — | — | WO | claimed |
| US-20060014790-A1 | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | claimed |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | claimed |
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135581-A1 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ASPH, DNPEP, APP | CYP2A6 1796/4885CYP17A1 1866/4885 |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | CYP2A6 3498/4885CYP17A1 3678/4885 |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ASPH, DNPEP, APP | CYP2A6 1796/4885CYP17A1 1866/4885 |
| US-20060014790-A1 | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | ASPH, DNPEP, ACE | CYP2A6 1901/4885CYP17A1 1051/4885 |
| US-20070149584-A9 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ASPH, DNPEP, APP | CYP2A6 1796/4885CYP17A1 1866/4885 |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | DNPEP, MME, ANPEP | CYP2A6 3498/4885CYP17A1 3678/4885 |
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ASPH, DNPEP, APP | CYP2A6 1719/4885CYP17A1 1908/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | CYP2A6 3498/4885CYP17A1 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.